Advanced biliary tract cancer (BTC) includes cholangiocarcinoma, gallbladder carcinoma, and ampullary carcinoma. BTC is a ...

How would you summarize your study for a lay audience? Advanced biliary tract cancer (BTC) includes cholangiocarcinoma, gallbladder carcinoma, and ampullary carcinoma. BTC is a rare and aggressive ...

Compass Therapeutics' tovecimig shows promise in biliary cancer, boasting a 17.1% response rate. Despite high risks, I ...

How would you summarize your study for a lay audience?Advanced biliary tract cancer (BTC) includes cholangiocarcinoma, gallbladder carcinoma, and ...

Dr. Falk Pharma, a research-based pharmaceutical company specializing in digestive and metabolic medicine, today announced positive results from its pivotal, phase 3 trial (NUC-5) on norucholic acid ...

The cholangioscopy market is anticipated to grow at a CAGR of 7.19% from US$10.476 billion in 2025 to US$14.820 billion by ...

"This positive CHMP opinion is a welcome step for physicians and patients in Europe who face a critical unmet need in HER2-positive biliary tract cancers, a rare and aggressive group of cancers ...

1 Department of Clinical Laboratory, Shandong Provincial Third Hospital, Shandong University, Jinan, Shandong, China 2 Department of Medical Engineering, Shandong Province Third Hospital, Shandong ...

Selective deep cannulation of the common bile duct remains the key rate-limiting step in successful endoscopic retrograde cholangiopancreatography (ERCP), especially in benign biliary disease.

Incyte (Nasdaq: INCY) today announced that multiple abstracts featuring new data from its oncology portfolio will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, ...